Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphomaSarit Assouline, Peter Martin, Bruce D. Cheson et al.|Blood Cancer Journal|2014Cited by 48